Cardio Diagnostics Holdings reported revenue of $34,890 for FY2024, up from $17,065 in 2023, while net loss remained stable at $8.38 million. The company expanded its product portfolio with the launch of HeartRisk™, a cardiovascular disease risk intelligence platform, and established partnerships with seven new provider organizations across multiple states.The company strengthened its financial position through an At-the-Market offering raising net proceeds of $14.68 million and a private placement generating $1 million. Additionally, Cardio received Medicare pricing determination from CMS for its PrecisionCHD™ and Epi+Gen CHD™ tests.Looking ahead, Cardio faces regulatory changes as the FDA's final rule on Laboratory Developed Tests takes effect in May 2025. The company is evaluating its regulatory strategy while focusing on expanding clinical evidence, leveraging newly awarded CPT PLA codes, and scaling internal operations capabilities.

Cardio Diagnostics Holdings reported revenue of $34,890 for FY2024, up from $17,065 in 2023, while net loss remained stable at $8.38 million. The company expanded its product portfolio with the launch of HeartRisk™, a cardiovascular disease risk intelligence platform, and established partnerships with seven new provider organizations across multiple states.The company strengthened its financial position through an At-the-Market offering raising net proceeds of $14.68 million and a private placement generating $1 million. Additionally, Cardio received Medicare pricing determination from CMS for its PrecisionCHD™ and Epi+Gen CHD™ tests.Looking ahead, Cardio faces regulatory changes as the FDA's final rule on Laboratory Developed Tests takes effect in May 2025. The company is evaluating its regulatory strategy while focusing on expanding clinical evidence, leveraging newly awarded CPT PLA codes, and scaling internal operations capabilities.